Afatinib for the treatment of non-small cell lung cancer

Bibliography

• American Cancer Society, Cancer facts and figures 2015
   Google Scholar
• Genova C, Rijavec E, Truini A, et al. Pemetrexed for the treatment of non-small cell lung cancer. Expert Opin Pharmacother 2013;14(11):1545-58
   PubMed Web of Science ®Google Scholar
• Aita M, Fasola G, Defferrari C, et al. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer. Crit Rev Oncol Hematol 2008;68(3):183-96
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46
   PubMed Web of Science ®Google Scholar
• Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010;28(2):357-60
   PubMed Web of Science ®Google Scholar
• Lin Y, Wang X, Jin H. EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. Am J Cancer Res 2014;4(5):411-35
   PubMed Web of Science ®Google Scholar
• Solca F, Dahl G, Zoephel A, et al. Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB family blocker. J Pharmacol Exp Ther 2012;343(2):342-50
   PubMed Web of Science ®Google Scholar
• Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008;27(34):4702-11
   PubMed Web of Science ®Google Scholar
• Stopfer P, Marzin K, Narjes H, et al. Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers. Cancer Chemother Pharmacol 2012;69:1051-61
   PubMed Web of Science ®Google Scholar
• Murakami H, Tamura T, Takahashi T, et al. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). Cancer Chemother Pharmacol 2012;69:891-9
   PubMed Web of Science ®Google Scholar
• Katakami N, Atagi S, Goto K, et al. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol 2013;31(27):3335-41
   PubMed Web of Science ®Google Scholar
• Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefi tinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012;13:528-38
   PubMed Web of Science ®Google Scholar
• Schuler MH, Yang CH, Park K, et al. Continuation of afatinib beyond progression: Results of a randomized, open-label, phase III trial of afatinib plus paclitaxel (P) versus investigator’s choice chemotherapy (CT) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) progressed on erlotinib/gefitinib (E/G) and afatinib—LUX-Lung 5 (LL5). J Clin Oncol 2014;32(5 Suppl):Abstract 8019
   Google Scholar
• Soria JC, Felip E, Cobo M, et al. Afatinib (A) vs erlotinib (E) as second-line therapy of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following platinum-based chemotherapy: Overall survival (OS) analysis from the global phase III trial LUX-Lung 8 (LL8). J Clin Oncol 2015;33(Suppl):Abstract 8002
   Google Scholar
• Yang JC, Shih JY, Su WC, et al. Afatinib fot patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): s phase 2 trial. Lancet Oncol 2012;13(5):539-48
   PubMed Web of Science ®Google Scholar
• Sequist LV, Yang JCH, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3327
   PubMed Web of Science ®Google Scholar
• Wu YL, Zhou C, Hu CP, et al. LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. J Clin Oncol 2013;31(Suppl):Abstract 8016
   Google Scholar
• Yang JCH, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6):analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015;16:141-51
   PubMed Web of Science ®Google Scholar
• Bar J, Botser D, Navon R, et al. A single-arm phase II study of afatinib treatment for advanced EGFR-mutant non-small cell lung cancer (mNSCLC) patients (pts) with EGFR-tyrosine kinase inhibitor (TKI) resistance. J Clin Oncol 2015;33(Suppl):Abstract e19031
   Google Scholar
• Cappuzzo F, Finocchiaro G, Grossi F, et al. Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer. J Thorac Oncol 2015;10(4):665-72
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Smit EF, Groen HJM, et al. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. Cancer Discov 2014;4(9):1036-45
   PubMed Web of Science ®Google Scholar
• Ahn MJ, Lee JY, Sun JM, et al. A phase Ib/II study of afatinib in combination with nimotuzumab in non-small cell lung cancer patients with acquired resistance to gefitinib or erlotinib. J Clin Oncol 2015;33(Suppl):Abstract 8086
   Google Scholar
• Yap TA, Vidal L, Adam J, et al. Phase I trial of the irreversibile EGFR and HER 2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 2010;28(25):3965-72
   PubMed Web of Science ®Google Scholar
• Available from: http://www.accessdata.fda.gov/drugsatfda_docs-7label/2013/201292s000lbl.pdf
   Google Scholar
• Available from: http://ema.europa.eu/docs/en_GB/document_library/EPAR_-_product_information/human/00280/WC500152392.pdf
   Google Scholar
• Janne PA, Ramalingam SS, Yang JCH, et al. Clinica lactivity of the mutant-selective inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant Non-small cell lung cancer (NSCLC). J Clin Oncol 2014;32:5s
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Rukazenkov Y, Thomas K, et al. A randomized, phase III study (FLAURA) of AZD9291, a novel EGFR-TKI, versus gefitinib or erlotinib in treratment-naive patients with advanced non-small cell lung cancer and an EGFR-TKI-sensitizing mutation. J Clin Oncol 2015;33
   Google Scholar
• Sequist LV, Soria JC, Goldman JW, et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med 2015;372(18):1700-9
   PubMed Web of Science ®Google Scholar
• Haaland B, Tan PS, de Castro P, et al. Meta-analysis of first-line therapies in advanced non–small-cell lung cancer harboring EGFR-activating mutation. J Thorac Oncol 2014;9(6):805-11
   PubMed Web of Science ®Google Scholar
• Yang JC, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol 2015;16(7):830-8
   PubMed Web of Science ®Google Scholar